ATE422901T1 - Granulocyte-macrophage colony-stimulating factor (gm-csf) als heilmittel für nervenschäden - Google Patents
Granulocyte-macrophage colony-stimulating factor (gm-csf) als heilmittel für nervenschädenInfo
- Publication number
- ATE422901T1 ATE422901T1 AT05025862T AT05025862T ATE422901T1 AT E422901 T1 ATE422901 T1 AT E422901T1 AT 05025862 T AT05025862 T AT 05025862T AT 05025862 T AT05025862 T AT 05025862T AT E422901 T1 ATE422901 T1 AT E422901T1
- Authority
- AT
- Austria
- Prior art keywords
- nerve
- substance
- dendritic cells
- csf
- remedy
- Prior art date
Links
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 title abstract 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 title abstract 3
- 208000028389 Nerve injury Diseases 0.000 title 1
- 230000008764 nerve damage Effects 0.000 title 1
- 239000000126 substance Substances 0.000 abstract 7
- 210000004443 dendritic cell Anatomy 0.000 abstract 4
- 230000001939 inductive effect Effects 0.000 abstract 3
- 210000005036 nerve Anatomy 0.000 abstract 3
- 108010025020 Nerve Growth Factor Proteins 0.000 abstract 2
- 102000007072 Nerve Growth Factors Human genes 0.000 abstract 2
- 210000003169 central nervous system Anatomy 0.000 abstract 2
- 206010008118 cerebral infarction Diseases 0.000 abstract 2
- 208000026106 cerebrovascular disease Diseases 0.000 abstract 2
- 230000006378 damage Effects 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 210000000944 nerve tissue Anatomy 0.000 abstract 2
- 239000003900 neurotrophic factor Substances 0.000 abstract 2
- 230000002062 proliferating effect Effects 0.000 abstract 2
- 208000020431 spinal cord injury Diseases 0.000 abstract 2
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 abstract 1
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 abstract 1
- 108090001005 Interleukin-6 Proteins 0.000 abstract 1
- 102100029268 Neurotrophin-3 Human genes 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 238000001990 intravenous administration Methods 0.000 abstract 1
- 210000002540 macrophage Anatomy 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 210000000274 microglia Anatomy 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 230000008929 regeneration Effects 0.000 abstract 1
- 238000011069 regeneration method Methods 0.000 abstract 1
- 230000003248 secreting effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/204—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Psychology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001069123 | 2001-03-12 | ||
| JP2001338772 | 2001-11-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE422901T1 true ATE422901T1 (de) | 2009-03-15 |
Family
ID=26611082
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05025862T ATE422901T1 (de) | 2001-03-12 | 2002-03-12 | Granulocyte-macrophage colony-stimulating factor (gm-csf) als heilmittel für nervenschäden |
| AT02702914T ATE365561T1 (de) | 2001-03-12 | 2002-03-12 | Verwendung von interleukin-12 zur behandlung von nervenschäden |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02702914T ATE365561T1 (de) | 2001-03-12 | 2002-03-12 | Verwendung von interleukin-12 zur behandlung von nervenschäden |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20040120925A1 (de) |
| EP (2) | EP1723969B1 (de) |
| JP (1) | JP3607271B2 (de) |
| AT (2) | ATE422901T1 (de) |
| CA (1) | CA2441434A1 (de) |
| DE (2) | DE60220894T2 (de) |
| WO (1) | WO2002072144A1 (de) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69821011T3 (de) | 1997-10-02 | 2009-01-08 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Verfahren zur Modulierung der Neovaskularisierung und/oder des Wachstums kollateraler Arterien und/oder anderer Arterien aus bestehenden arteriolären Verbindungen |
| FR2834898B1 (fr) * | 2002-01-18 | 2005-06-10 | Didier Pourquier | Nouvelle application therapeutique du g-csf, du gm-csf et du scf |
| EP1489163A4 (de) * | 2002-03-27 | 2007-08-08 | Inst Of Gene And Brain Science | Verfahren zur induzierung des wachstums von nervenstammzellen |
| AU2003250697B2 (en) * | 2002-07-30 | 2008-05-01 | Stem Cell Therapeutics Inc. | Oligodendrocyte production from multipotent neural stem cells |
| US7785601B2 (en) | 2002-12-31 | 2010-08-31 | Sygnis Bioscience Gmbh & Co. Kg | Methods of treating neurological conditions with hematopoietic growth factors |
| AU2003299430B2 (en) * | 2002-12-31 | 2009-01-08 | Neurovision-Pharma Gmbh | Methods of treating neurological conditions with hematopoeitic growth factors |
| US7695723B2 (en) | 2002-12-31 | 2010-04-13 | Sygnis Bioscience Gmbh & Co. Kg | Methods of treating neurological conditions with hematopoietic growth factors |
| US7569545B2 (en) * | 2005-05-20 | 2009-08-04 | Academia Sinica | Methods of increasing neurotrophic factor expression |
| US20070099867A1 (en) * | 2005-05-24 | 2007-05-03 | Glycoscience Laboratories, Inc. | Pharmaceutical agent containing hyaluronan as an active ingredient |
| JP2009091248A (ja) * | 2006-01-17 | 2009-04-30 | Toshitsu Kagaku Kenkyusho:Kk | 外傷性神経障害および／または運動機能障害の治療薬 |
| AU2007219714A1 (en) * | 2006-02-28 | 2007-09-07 | Regenertech Pty Limited | Tissue regeneration II |
| CU23526B6 (es) | 2006-10-03 | 2010-05-19 | Ct Ingenieria Genetica Biotech | Método para la restauración morfofuncional de nervios periféricos en la neuropatía diabética |
| CA2641571C (en) | 2006-12-05 | 2010-01-19 | Glycoscience Laboratories, Inc. | Treatment of osteoarthritis |
| US20140178335A1 (en) * | 2011-07-27 | 2014-06-26 | Neumedicines, Inc. | Use of il-12 to generate endogenous erythropoietin |
| CN107148278B (zh) * | 2014-08-15 | 2021-06-29 | 财团法人卫生研究院 | 利用神经干细胞与IL12p40增强神经再生的方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5650148A (en) * | 1988-12-15 | 1997-07-22 | The Regents Of The University Of California | Method of grafting genetically modified cells to treat defects, disease or damage of the central nervous system |
| DE4019208A1 (de) * | 1990-06-15 | 1992-03-05 | Peter Dr Med Wehling | Nervenregenerationsmittel |
| JPH05148155A (ja) * | 1991-11-28 | 1993-06-15 | Toray Ind Inc | 神経栄養薬 |
| JPH05213767A (ja) * | 1992-02-07 | 1993-08-24 | Mochida Pharmaceut Co Ltd | 脳神経疾患治療剤 |
| EP0599303A3 (de) * | 1992-11-27 | 1998-07-29 | Takeda Chemical Industries, Ltd. | Peptide-Konjugate |
| GB9506466D0 (en) * | 1994-08-26 | 1995-05-17 | Prolifix Ltd | Cell cycle regulated repressor and dna element |
| JPH08176008A (ja) * | 1994-12-27 | 1996-07-09 | Toray Ind Inc | 神経栄養薬 |
| JP2000510813A (ja) * | 1995-02-06 | 2000-08-22 | ジェネテイックス・インスティテュート・インコーポレイテッド | Ｉｌ−１２用処方 |
| US6267955B1 (en) * | 1995-09-15 | 2001-07-31 | Yeda Research And Development Co. Ltd. | Mononuclear phagocytes and their use to promote axonal regeneration |
| US5800812A (en) * | 1995-09-15 | 1998-09-01 | Yeda Research And Development Co. Ltd. | Methods of use of mononuclear phagocytes to promote axonal regeneration |
| US5837231A (en) * | 1996-06-27 | 1998-11-17 | Regents Of The University Of Minnesota | GM-CSF administration for the treatment and prevention of recurrence of brain tumors |
| CA2213906A1 (en) * | 1996-09-23 | 1998-03-23 | Dusica Maysinger | Pharmaceutical composition and method for neuron rescue in ischemic stroke |
| US6167888B1 (en) * | 1997-06-30 | 2001-01-02 | The Regents Of The University Of California | Method for inducing partial recovery of lost voluntary motor function after spinal cord injury in a mammal |
| WO1999016460A2 (en) * | 1997-09-30 | 1999-04-08 | Duke University | Apolipoprotein e/growth factor complexes and methods of use |
-
2002
- 2002-03-12 AT AT05025862T patent/ATE422901T1/de not_active IP Right Cessation
- 2002-03-12 EP EP05025862A patent/EP1723969B1/de not_active Expired - Lifetime
- 2002-03-12 DE DE60220894T patent/DE60220894T2/de not_active Expired - Fee Related
- 2002-03-12 JP JP2002571102A patent/JP3607271B2/ja not_active Expired - Fee Related
- 2002-03-12 WO PCT/JP2002/002310 patent/WO2002072144A1/ja not_active Ceased
- 2002-03-12 AT AT02702914T patent/ATE365561T1/de not_active IP Right Cessation
- 2002-03-12 EP EP02702914A patent/EP1374898B1/de not_active Expired - Lifetime
- 2002-03-12 US US10/471,448 patent/US20040120925A1/en not_active Abandoned
- 2002-03-12 DE DE60231263T patent/DE60231263D1/de not_active Expired - Fee Related
- 2002-03-12 CA CA002441434A patent/CA2441434A1/en not_active Abandoned
-
2006
- 2006-10-06 US US11/539,476 patent/US20070243160A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP3607271B2 (ja) | 2005-01-05 |
| US20070243160A1 (en) | 2007-10-18 |
| EP1374898A4 (de) | 2004-07-28 |
| CA2441434A1 (en) | 2002-09-19 |
| DE60220894D1 (de) | 2007-08-09 |
| DE60231263D1 (de) | 2009-04-02 |
| JPWO2002072144A1 (ja) | 2004-07-02 |
| WO2002072144A9 (en) | 2002-12-27 |
| EP1374898B1 (de) | 2007-06-27 |
| ATE365561T1 (de) | 2007-07-15 |
| US20040120925A1 (en) | 2004-06-24 |
| EP1723969A1 (de) | 2006-11-22 |
| WO2002072144A1 (en) | 2002-09-19 |
| EP1374898A1 (de) | 2004-01-02 |
| EP1723969B1 (de) | 2009-02-18 |
| DE60220894T2 (de) | 2008-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE422901T1 (de) | Granulocyte-macrophage colony-stimulating factor (gm-csf) als heilmittel für nervenschäden | |
| Jia et al. | Sciatic nerve repair by acellular nerve xenografts implanted with BMSCs in rats xenograft combined with BMSCs | |
| Boido et al. | Mesenchymal stem cell transplantation reduces glial cyst and improves functional outcome after spinal cord compression | |
| KR102353601B1 (ko) | 줄기세포의 면역조절성 효과의 조절 방법 | |
| Guenard et al. | Peripheral nerve regeneration is impeded by interleukin‐1 receptor antagonist released from a polymeric guidance channel | |
| Shoichet et al. | Strategies for regeneration and repair in the injured central nervous system | |
| Pettingill et al. | Neurotrophic factors and neural prostheses: potential clinical applications based upon findings in the auditory system | |
| F. Azari et al. | Mesenchymal stem cells for treatment of CNS injury | |
| Lien et al. | Enhancing peripheral nerve regeneration with neurotrophic factors and bioengineered scaffolds: A basic science and clinical perspective | |
| ATE201827T1 (de) | Methoden und mittel zur förderung der wundheilung | |
| Lucia Maria Ferri et al. | Mesenchymal stem cells for ischemic stroke: progress and possibilities | |
| DE4219626A1 (de) | Methode zur Einschleusung therapeutisch relevanter Gene in Körperzellen | |
| MX9707669A (es) | Uso del factor neurotrofico glial (gdnf) para el tratamiento de padecimientos del oido. | |
| WO2005000215A3 (en) | Methods for treating pain | |
| Chen et al. | Mesenchymal stem cell transplantation: neuroprotection and nerve regeneration after spinal cord injury | |
| Asgharzade et al. | A review on stem cell therapy for neuropathic pain | |
| Hirota et al. | Local application of a transcutaneous carbon dioxide paste prevents excessive scarring and promotes muscle regeneration in a bupivacaine‐induced rat model of muscle injury | |
| Feng et al. | Graft of pre-injured sural nerve promotes regeneration of corticospinal tract and functional recovery in rats with chronic spinal cord injury | |
| McConnell et al. | In vivo induction and delivery of nerve growth factor, using HEK-293 cells | |
| Richard et al. | Elucidating the pivotal neuroimmunomodulation of stem cells in spinal cord injury repair | |
| Alton et al. | Progress and prospects: gene therapy clinical trials (part 2) | |
| Maguire et al. | The systems biology of stem cell released molecules—based therapeutics | |
| Dijkhuizen et al. | The use of neurotrophic factors to treat spinal cord injury: advantages and disadvantages of different delivery methods | |
| Donegà et al. | Systemic neural stem cell-based therapeutic interventions for inflammatory CNS disorders | |
| Seo et al. | Early immunomodulation by intravenously transplanted mesenchymal stem cells promotes functional recovery in spinal cord injured rats |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |